A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Portola
Protocol Number
Portola Pharmaceuticals 13-601
Cancer Diagnosis
To Learn More Call
201-510-0910